Xencor's reported revenue has swung sharply from $70.0M in 4Q24 to $4.5M in 1Q26 before rebounding to $116.5M in 3Q26, suggesting growth depends on irregular milestone and upfront payments rather than steady royalty expansion.
Price trend, volume and key moving averages
Trailing total returns as of 11/14/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.50+249.6% vs -$0.33 | $117M+85.0% vs $63M |
Q3 2026 Aug 5, 2026 | -$0.29+63.8% vs -$0.80 | $51M+171.2% vs $19M |
Q2 2026 May 6, 2026 | -$1.71-163.1% vs -$0.65 | $5M-83.8% vs $28M |
Q1 2026 Feb 25, 2026 | -$0.09+85.9% vs -$0.64 | $28M-5.8% vs $30M |
Xencor (XNCR) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.08 per share a year ago.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2026. “Xencor's lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a mono.
Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. XmAb819 achieved a 45.5% cORR at 400 mcg/kg, supporting advancement toward FDA Accelerated Approval discussions in 1H 2027 and a phase 3 trial by late 2027. The company is expanding XmAb819 into other ENPP3+ solid tumors and progressing XmAb942 in phase 2b for ulcerative colitis, with interim data expected by end of 2026.
Xencor NASDAQ: XNCR reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The company said it selected a 400 microgram-per-kilogram intravenous target dose for planned late-stage development and expects to begin a registration-enabling study in 2027.
Benchmark XNCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Xencor, Inc. (XNCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.09 | $2.75B | -24.66 | 13.65% | -58.79% | -21.29% | — | |
| $17.43 | $2.19B | -4.99 | -4.26% | -445% | -90.04% | — | |
| $2.20 | $139.84M | -9.59 | 0.78% | -8.7% | -31.27% | — | |
| $34.18 | $7.05B | -13.88 | — | -7173.52% | -63.01% | — | |
| $47.03 | $7.89B | -9999.00 | -5.25% | -0.02% | -0.02% | — | |
| $26.24 | $1.93B | 46.20 | 38.87% | 16.28% | 22.48% | — |
Xencor, Inc. (XNCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Xencor, Inc. (XNCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Oct 26, 2026·SEC
Aug 5, 2026·SEC
Get notified when XNCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Xencor, Inc. (XNCR) stock FAQ — growth, dividends, profitability & financials explained
Xencor, Inc. (XNCR) reported $200.5M in revenue over the trailing twelve months. Revenue was $125.6M in fiscal year 2025. That is 1733% more than the $6.8M of fiscal year 2011.
Xencor, Inc. (XNCR) grew revenue by 19.8% over the trailing twelve months, compared with the twelve months before.
No. Xencor, Inc. (XNCR) reported a net loss of $117.9M over the trailing twelve months.
Xencor, Inc. (XNCR) had a return on equity (ROE) of -21.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
Xencor, Inc. (XNCR) had negative free cash flow of $176.4M over the trailing twelve months.
